Perampanel
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Perampanel. Perampanel is a post-synaptic AMPA receptor antagonist. It enhances the glutamate pathway. Fully referenced neurology checklist.
Mode of action
- Perampanel is a post-synaptic AMPA receptor antagonist
- It enhances the glutamate pathway
- It decreases excitatory synaptic transmission
Indications (adjunctive)
Locked: subscribe to see this section.
Dosing
Locked: subscribe to see this section.
Psychiatric side effects (mild)
Locked: subscribe to see this section.
Neurological side effects
Locked: subscribe to see this section.
Systemic side effects
Locked: subscribe to see this section.
Precautions
Locked: subscribe to see this section.
References
- Schulze-Bonhage A, Hintz M. Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability. Patient Prefer Adherence 2015; 9:1143-1151.
- Ledingham DR, Patsalos PN. Perampanel: what is its place in the management of partial onset epilepsy? Neurol Ther 2013; 2:13-24.
- Besag FM, Patsalos PN. Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures. Neuropsychiatr Dis Treat 2016; 12:1215-1220.
- Greenwood J, Valdes J. Perampanel (fycompa): a review of clinical efficacy and safety in epilepsy. P T 2016; 41:683-698.
- Cada DJ, Levien TL, Baker DE. Perampanel. Hosp Pharm 2013; 48:321-331.
- And 3 more. Subscribe to see the full list
